New CTx-1301 Data Affirms Pharmacokinetic Profile to Treat ADHD
Psychiatric Times
New clinical data confirms the pharmacokinetic profile of CTx-1301, supporting its potential as a treatment for attention-deficit/hyperactivity disorder. The findings affirm the compound's suitability for advancing into further stages of ADHD therapy development.
All articles from 12 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.